Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression
Data Collection
Mental Disorders+2
+ Behavioral Symptoms
+ Depression
Treatment Study
Summary
Study start date: November 1, 2003
Actual date on which the first participant was enrolled.duloxetine 60mg - 120mg, escitalopram 10mg - 20mg, and placebo, 8-month,
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.675 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Must be at least 18 of age * Must meet the criteria for major depressive disorder * You must be able to visit the doctor's office about once a week for 2 to 3 months. After that, you will need to visit the doctor's office once a month for about 6 months * You must be able to take the study drug as prescribed (6 capsules per day taken once-daily) Exclusion Criteria: * You are a woman and are pregnant or breastfeeding. * You have a current or previous major psychiatric disorder other than depression, such as bipolar disorder, schizophrenia, or other psychotic disorder. * You have a history of alcohol or drug dependence within the past 6 months
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Cincinnati, United StatesSee the location